慢性丙型肝炎基因1型患者抗病毒治疗对丙型肝炎病毒核心抗原、肝脂肪变性和纤维化的影响

doi:10.19871/j.cnki.xfcrbzz.2024.06.010

新发传染病电子杂志 ›› 2024, Vol. 9 ›› Issue (6): 54-59.doi: 10.19871/j.cnki.xfcrbzz.2024.06.010

慢性丙型肝炎基因1型患者抗病毒治疗对丙型肝炎病毒核心抗原、肝脂肪变性和纤维化的影响

高兴娟¹, 程磊¹, 马秀清¹, 刘守珠¹, 王宝英¹, 刘海燕², 才德吉², 杨兴唐¹

1.青海红十字医院检验科,青海西宁 810001;
2.青海红十字医院感染科,青海西宁 810001

收稿日期:2024-03-15 出版日期:2025-01-25 发布日期:2025-01-25
通讯作者: 杨兴唐,Email：yxt19820928@163.com
基金资助:
青海省科技厅指导性计划项目 ( 2022-ZJ-766 )

Effects of antiviral therapy on HCV core antigen, hepatic steatosis, and fibrosis in patients with chronic hepatitis C genotype 1

Gao Xingjuan¹, Cheng Lei¹, Ma Xiuqing¹, Liu Shouzhu¹, Wang Baoying¹, Liu Haiyan², Cai Deji², Yang Xingtang¹

1. Department of Clinical Laboratory, Qinghai Red Cross Hospital, Qinghai Xining 810001,China;
2. Department of Infectious Diseases, Qinghai Red Cross Hospital, Qinghai Xining 810001, China

Received:2024-03-15 Online:2025-01-25 Published:2025-01-25

摘要/Abstract

摘要： 目的探讨慢性丙型肝炎（chronic hepatitis C,CHC）基因1型患者接受直接抗病毒药物（direct-acting antiviral agent,DAA）治疗期间,丙型肝炎病毒核心抗原（hepatitis C virus core antigen,HCV Ag）、受控衰减参数（controlled attenuation parameter,CAP）和基于4项因素的肝纤维化指数（fibrosis index based on 4 factors,FIB-4）变化及与治疗结果的关系。方法选取2020年3月至2021年5月在青海红十字医院接受DAA治疗的51例CHC患者作为研究对象。12周时持续病毒学应答（sustained virologic response at 12 weeks,SVR12）定义为治疗结束12周时HCV RNA检测量低于12U/ml。在基线、治疗第4周、治疗第8周、治疗结束和治疗结束后12周时评估HCV Ag和HCV RNA水平。HCV Ag使用化学发光微粒子免疫检测法测定。在基线、治疗结束和治疗结束后12周时评估CAP和FIB-4。结果共49例（96.08%）患者在基线时HCV Ag（>3fmol/L）和HCV RNA均呈阳性,其余2例仅HCV RNA呈阳性（分别为124U/ml、876U/ml）。基线HCV Ag和HCV RNA存在正相关性（r=0.505,P<0.001）。在DAA治疗期间,56.86%的患者在治疗第4周、84.31%的患者在治疗第8周和100%的患者在治疗结束时未检出HCV Ag。治疗结束后12周,共49例（96.08%）患者获得SVR12,且HCV Ag和HCV RNA检测一致性较高。治疗第4周和治疗第8周的HCV Ag和HCV RNA在预测SVR12时均具有较高的阳性预测值。与基线相比,治疗结束后12周时CAP值显著增加（P<0.05）;治疗结束时和治疗结束后12周时FIB-4值均显著下降（P<0.05）,且治疗结束后12周时FIB-4较治疗结束时进一步下降（P<0.05）。治疗结束后12周时FIB-4较基线值变化值与基线HCV Ag存在正相关关系（r=0.297,P<0.05）。结论 DAA治疗可改善患者的肝纤维化,同时肝脂肪变性有增加趋势。在DAA治疗期间,使用HCV Ag可以监测HCV基因1型患者的治疗效果。

关键词: 慢性丙型肝炎, 直接抗病毒药物, 丙型肝炎病毒核心抗原, 受控衰减参数, 基于4项因素的肝纤维化指数

Abstract: Objective To determine the changes in hepatitis C virus core antigen (HCV Ag), controlled attenuation parameter (CAP), and fibrosis index based on 4 factors (FIB-4) during direct antiviral agent (DAA) treatment in patients with chronic hepatitis C (CHC) genotype 1, and their relationship with treatment outcomes. Method Fifty-one CHC patients who were treated with DAA in Our hospital from March 2020 to May 2021 were selected as the study objects. Sustained virological response (SVR) 12 was defined as a sustained virological response of less than 12U/ml at the end of 12 weeks of treatment HCV Ag and HCV RNA levels were assessed at baseline, 4 weeks of treatment, 8 weeks of treatment, at the end of treatment, and 12 weeks after the end of treatment. HCV Ag was determined by chemiluminescent microparticle immunoassay. CAP and FIB-4 were assessed at baseline, at the end of treatment, and 12 weeks after treatment. Result A total of 49 patients (96.08%) were positive for both HCV Ag (>3fmol/L) and HCV RNA at baseline, and the remaining 2 patients were positive only for HCV RNA (124U/ml and 876U/ml, respectively). By SPSS Spearman rank correlation analysis, there was a significant positive correlation between HCV Ag and HCV RNA at baseline (P< 0.001). During DAA treatment, 56.86% of patients had no detectable HCV Ag at week 4, 84.31% at week 8, and 100% at the end of treatment. Twelve weeks after the end of treatment, 49 patients (96.08%) achieved SVR 12, and HCV Ag and HCV RNA tests were highly consistent. Both HCV Ag and HCV RNA at 4 and 8 weeks of treatment had higher positive predictive values in predicting SVR12. CAP values were significantly increased at 12 weeks after treatment compared with baseline (P<0.05). FIB-4 values at the end of treatment and 12 weeks after treatment were significantly decreased (P<0.05), and FIB-4 was further decreased at 12 weeks after treatment than at the end of treatment (P<0.05). Finally, there was a positive correlation between the change in FIB-4 from baseline and baseline HCV Ag at 12 weeks after treatment (P<0.05). Conclusion During DAA treatment, the use of HCV Ag can monitor the treatment outcomes of genotype 1 HCV patients, and DAA improves liver fibrosis in patients. On the other hand, there is an increasing trend of liver steatosis.

Key words: Chronic hepatitis C, Direct antiviral agent, Hepatitis C virus core antigen, Controlled attenuation parameter, Fibrosis index based on the 4 factors

中图分类号:

R512.6+3

高兴娟, 程磊, 马秀清, 刘守珠, 王宝英, 刘海燕, 才德吉, 杨兴唐. 慢性丙型肝炎基因1型患者抗病毒治疗对丙型肝炎病毒核心抗原、肝脂肪变性和纤维化的影响[J]. 新发传染病电子杂志, 2024, 9(6): 54-59.

Gao Xingjuan, Cheng Lei, Ma Xiuqing, Liu Shouzhu, Wang Baoying, Liu Haiyan, Cai Deji, Yang Xingtang. Effects of antiviral therapy on HCV core antigen, hepatic steatosis, and fibrosis in patients with chronic hepatitis C genotype 1[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(6): 54-59.

参考文献

[1] UMAROV FK.Epidemiology of Hepatitis C and its Development[J]. Res, Trauma Disabil, 2023, 2(4): 1-6.
[2] 付小义,金娴,徐晓婧,等.泛基因型DAA治疗慢性丙型肝炎[J/CD].新发传染病电子杂志,2018,3(1):30-33.
[3] SHEN C, JIANG X, LI M, et al.Hepatitis virus and hepatocellular carcinoma: Recent advances[J]. Cancers, 2023, 15(2): 533-555.
[4] 喻苧,樊蓉. 慢性乙型肝炎和慢性丙型肝炎抗病毒治疗疗效评价指标[J]. 中国实用内科杂志,2023,43(5):369-374.
[5] LIN SF, TUNG SY, WEI KL, et al.Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C[J]. PLoS One, 2020, 15(3): e0229994.
[6] WANG Y, JIE W, LING J, et al.HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection[J]. J Clin Lab Anal, 2021, 35(6): e23755.
[7] 马亚楠,刘近春. 受控衰减参数无创定量诊断肝脂肪变性的研究进展[J]. 胃肠病学和肝病学杂志,2020,29(11):1309-1312,1316.
[8] CATANZARO R, ALEO A, SCIUTO M, et al.FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study[J]. Clin Exp Hepatol, 2021, 7(1): 111-116.
[9] LEE YC, HU TH, HUNG CH, et al.The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals[J]. PLoS One, 2019, 14(4): e0214323.
[10] SHIMIZU K, SOROIDA Y, SATO M, et al.Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter[J]. Sci Rep, 2018, 8(1): 7845-7849.
[11] ROUT G, NAYAK B, PATEL AH, et al.Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography[J]. J Clin Exp Hepatol, 2019, 9(2): 207-214.
[12] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志,2019,27(12):962-979.
[13] STERLING RK, LISSEN E, CLUMECK N, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43(6): 1317-1325.
[14] UCEJKO M, TOMASIEWICZ K, OLCZAK A, et al.Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals[J]. Br J Biomed Sci, 2019, 76(4): 190-194.
[15] ROSSETTI B, LOGGI E, RAFFAELLI CS, et al.Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era[J]. New Microbiol, 2021, 44(2): 89-94.
[16] SEPÚLVEDA-CRESPO D, TREVIÑO-NAKOURA A, BELLON JM, et al. Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals[J]. Aliment Pharmacol Ther, 2022, 56(8): 1224-1234.
[17] PONNUVEL S, PRAKASH A, STEVE RJ, et al.Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs[J]. PLoS One, 2023, 18(2): e0282013.
[18] TRIFAN A, STRATINA E, ROTARU A, et al.Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response[J]. Diagnostics (Basel), 2022, 12(3): 702-712.
[19] NIU B, ZANG W, ZHOU H, et al.Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment[J]. BMC Gastroenterol, 2023, 23(1): 102-113.
[20] HUYNH T, MA S, HU KQ.HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB-4 scores[J]. Hepatol Commun, 2022, 6(12): 3496-3504.

慢性丙型肝炎基因1型患者抗病毒治疗对丙型肝炎病毒核心抗原、肝脂肪变性和纤维化的影响

Effects of antiviral therapy on HCV core antigen, hepatic steatosis, and fibrosis in patients with chronic hepatitis C genotype 1

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	付小义, 金娴, 徐晓婧, 彭雁忠. 泛基因型DAA治疗慢性丙型肝炎[J]. 新发传染病电子杂志, 2018, 3(1): 30-33.
[2]	苏冬娜, 吴诗品. 慢性丙型病毒性肝炎患者PBMC中2-5AS的表达及其与Stat1和Stat2水平相关性分析[J]. 新发传染病电子杂志, 2017, 2(2): 81-84.